In the phase I/II BRUIN trial, results of which were published by Mato et al in The New England Journal of Medicine, researchers tested the efficacy of pirtobrutinib in pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
